Filana Therapeutics (FLNA) Non-Current Assets (2010 - 2026)

Filana Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $20.2 million in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 1.86% year-over-year to $20.2 million in Q2 2026; TTM through Jun 2026 was $82.1 million, a 1.79% decrease from a year earlier, with the FY2025 full-year figure at $20.6 million, down 1.69% from the prior year.
• Non-Current Assets was $20.2 million for Q2 2026 at Filana Therapeutics, down from $20.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $24.0 million in Q3 2022, with the low at $20.2 million in Q2 2026.
• Average Non-Current Assets over 5 years is $21.8 million, with a median of $21.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 7643.31% in 2022, then retreated 6.95% in 2023.
• Over 5 years, Non-Current Assets stood at $23.6 million in 2022, then retreated by 6.68% to $22.0 million in 2023, then retreated by 4.67% to $21.0 million in 2024, then fell by 1.69% to $20.6 million in 2025, then fell by 2.26% to $20.2 million in 2026.
• The last three Non-Current Assets figures came in at $20.2 million (Q2 2026), $20.4 million (Q1 2026), and $20.6 million (Q4 2025), per Business Quant data.